<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02410005</url>
  </required_header>
  <id_info>
    <org_study_id>14-00039</org_study_id>
    <secondary_id>NPRP No: 4-1392-3-345</secondary_id>
    <secondary_id>14-00039</secondary_id>
    <nct_id>NCT02410005</nct_id>
  </id_info>
  <brief_title>Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)</brief_title>
  <acronym>IDEAL</acronym>
  <official_title>Kidney Disease in Type 2 Diabetes Mellitus: Biomarker Discovery and Novel Therapeutics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Cornell Medical College in Qatar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hamad Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Cornell Medical College in Qatar</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single center open-label randomized controlled trial designed to evaluate the
      efficacy of calcitriol plus losartan therapy in subjects with type II diabetes and
      macroalbuminuria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose to test the efficacy and safety of a combined regimen of calcitriol
      and losartan in subjects with type II diabetes (T2DM) with macroalbuminuria. Should the
      investigators study confirm the hypothesis that the proposed novel regimen is superior to the
      current practice of renin-angiotensin-aldosterone system blockade, the study would
      significantly advance the care of subjects with type II diabetes and kidney disease in Qatar
      and worldwide. In this regard it is worth noting that the prevalence of end stage renal
      disease in Qatar is 202 subjects per million population. This would translate into fewer
      subjects requiring dialysis or transplantation, an enormous benefit to individuals and
      society.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Logistic challenges
  </why_stopped>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">September 7, 2015</completion_date>
  <primary_completion_date type="Actual">September 7, 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24h urine 24hr urine albuminuria</measure>
    <time_frame>12 month</time_frame>
    <description>24h urine albuminuria (log transformed) from baseline to 12 months post-randomization in the losartan plus calcitriol group compared to the losartan alone group.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Urine mRNA/miRNA expression</measure>
    <time_frame>15 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Urine Albumin-to-Creatinine Ratio (UACR)</measure>
    <time_frame>15 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood Pressure (BP)</measure>
    <time_frame>15 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Estimated glomuerula filtration rate (eGFR)</measure>
    <time_frame>15 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>Losartan alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the losartan alone group, subjects are prescribed: losartan 50mg twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Losartan and Calcitriol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the losartan plus calcitriol group, subjects are prescribed: losartan 50mg twice daily and calcitriol 0.25mcg daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcitriol</intervention_name>
    <arm_group_label>Losartan and Calcitriol</arm_group_label>
    <other_name>1,25-dihydroxycholecalciferol</other_name>
    <other_name>1,25-dihydroxyvitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <arm_group_label>Losartan alone</arm_group_label>
    <arm_group_label>Losartan and Calcitriol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of T2DM requiring treatment with at least one oral hypoglycemic medication
             or insulin

          2. Macroalbuminuria as defined as the presence of a UACR greater than 300 mg/gm
             creatinine (30 mg/mmol creatinine) on two occasions in the last six months

          3. Estimated eGFR of 30 to 90 mL/min/1.73 m2

        Exclusion Criteria:

          1. Positive Pregnancy Test or planning pregnancy in the subsequent 18months (if female)

          2. Serum Calcium &gt; 2.45 mmol/L (9.8 mg/dL)

          3. Serum Phosphorus &gt; 1.78 mmol/L (5.5 mg/dL)

          4. Serum Potassium &gt; 5.5 mmol/L (5 mEq/L)

          5. Parathyroid hormone &lt; 20 pg/mL or &gt; 500 pg/mL

          6. Hemoglobin A1C &gt; 12%

          7. 25-OH Vit D &gt; 50 ng/mL

          8. Poorly controlled hypertension defined as systolic blood pressure &gt;= 180 mm Hg or
             diastolic blood pressure &gt;= 110 mm Hg

          9. History of kidney stones

         10. History of severe disease like chronic liver disease

         11. Active malignancy

         12. Active granulomatous diseases like turburculosis and sarcoidosis

         13. Recent diagnosis of acute renal failure within 3 months of screening visit

         14. Likelihood of renal replacement therapy within 1 year

         15. History of parathyroidectomy

         16. Currently taking calcitriol or 1,25-dihydroxyvitamin D analog

         17. Currently taking calcitonin, bisphosphonates, cinacalcet, teriparatide,
             glucocorticoids or other drugs that may affect calcium or bone metabolism (subjects
             may be taking calcium containing phosphate binder or other phosphate binder. Subjects
             may also be taking stable dose of estrogen/progestin)

         18. History of osteoporosis or other bone disorder requiring calcitriol therapy

         19. History of allergic reaction to calcitriol, paracalcitol, hectoral, or other
             1,25-dihydroxyvitamin D analogs

         20. History of allergic reaction to losartan or any other angiotensin receptor blocker
             therapy

         21. Evidence of drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phyllis August, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College in Qatar</name>
      <address>
        <city>Doha</city>
        <zip>24144</zip>
        <country>Qatar</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamad Medical Corporation</name>
      <address>
        <city>Doha</city>
        <country>Qatar</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Qatar</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2015</study_first_submitted>
  <study_first_submitted_qc>April 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2015</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Dihydroxycholecalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

